Skip to main content

Table 5 Recommendations on the use of calcitonin gene-related peptide monoclonal antibodies for the prevention of episodic and chronic migraine

From: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Setting Drug Recommendation Quality of evidence Strength of the recommendation
Migraine prevention in patients with episodic migraine
 Eptinezumab 1000 mg quarterly Suggested LOW ↑? Weak
 Erenumab 70 mg monthly Recommended HIGH ↑↑ Strong
 Erenumab 140 mg monthly Recommended MEDIUM ↑↑Strong
 Fremanezumab 225 mg monthly Recommended HIGH ↑↑ Strong
 Fremanezumab 675 mg quarterly Recommended MEDIUM ↑↑Strong
 Galcanezumab 240 mg loading dose + 120 mg monthly Recommended MEDIUM ↑↑ Strong
 Galcanezumab 240 mg monthly Recommended MEDIUM ↑↑ Strong
Migraine prevention in patients with chronic migraine
 Erenumab 70 mg monthly Recommended MEDIUM ↑↑Strong
 Erenumab 140 mg monthly Recommended MEDIUM ↑↑Strong
 Fremanezumab 675 mg quarterly Recommended MEDIUM ↑↑Strong
 Fremanezumab 675 mg loading dose + 225 mg monthly Recommended HIGH ↑↑ Strong
 Galcanezumab 240 mg loading dose + 120 mg monthly Recommended MEDIUM ↑↑Strong
 Galcanezumab 240 mg monthly Recommended MEDIUM ↑↑Strong
  1. Symbols depict the strength of the recommendation according to the GRADE system